Promimic (PRO) Q2 2026 earnings summary

Executive summary

• Net sales for Q2 2026 reached 12.0 MSEK, up 6% year-over-year, with core business revenues growing 14% currency-adjusted.

• FDA approval was obtained for a new nanostructured ceramic implant surface, enabling commercial scaling and new market opportunities.

• Major customers in spine and dental segments reported strong growth, with Curiteva doubling production capacity and Alphatec Spine growing 17%.

• Cost control measures maintained profitability despite currency headwinds.

Financial highlights

• Q2 2026 net sales: 12.0 MSEK (11.3), operating income: -1.4 MSEK (-1.3), net result: -1.5 MSEK (-1.5).

• H1 2026 net sales: 20.8 MSEK (20.0), operating income: -4.9 MSEK (-4.9), net result: -5.0 MSEK (-6.0).

• Cash flow for Q2: -2.3 MSEK (-5.2), cash at period end: 19.8 MSEK (28.4).

• EBITDA for Q2: -22 TSEK (69), solid equity ratio at 80% (81%).

Outlook and guidance

• Focus remains on expanding in the US and new market segments, leveraging recent FDA approval.

• Royalty calculation changes in the dental segment expected to positively impact growth from Q3 onward.

• Strategic goal: >25% CAGR and >40% EBITDA margin long-term.